ArticleAging medicine (Milton (N.S.W))2025
Prognostic Analysis of Lung Cancer With Brain Metastases in Elderly Patients: A Multicenter Retrospective Study.
Article in Aging medicine (Milton (N.S.W)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05609162 (Effects of Local and Systemic Treatments in Brain Metastases With Poor Prognostic Factors), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Local and Systemic Treatments in Brain Metastases With Poor Prognostic Factors: Multicenter Retrospective Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore the prognostic factors affecting overall survival (OS) in patients aged ≥ 65 years with lung cancer BMs. Methods: In this multicenter retrospective study, 293 patients aged ≥ 65 years diagnosed with lung cancer BMs between 2010 and 2023 were included. We analyzed the correlation between clinical information, treatment methods, molecular data, and OS. Univariate and multivariate Cox regression models were used to identify risk factors, and Kaplan-Meier survival curves were constructed for analysis. Results: A total of 293 patients aged ≥ 65 years with lung cancer BMs were included (age mean [SD], 69.40 [4.04] years). Univariate analysis of 293 lung cancer patients aged ≥ 65 years with BMs showed that risk prognostic factors included pathological type (SCLC, hazard ratio [HR] = 2.221, 95% confidence interval [CI] = 1.531-3.224, Conclusions: Pathological type, KPS, and targeted therapy significantly impact OS in elderly lung cancer BM patients. Targeted therapy may be a promising option for improving prognosis in this patient population. Trial Registration: ClinicalTrials.gov identifier: NCT05609162.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.